Navigation Links
ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma

STRIBUTION PROGRAM. THIS PROGRAM IS CALLED "RevAssist(R)". UNDER THIS PROGRAM, ONLY PRESCRIBERS AND PHARMACISTS REGISTERED WITH THE PROGRAM CAN PRESCRIBE AND DISPENSE THE PRODUCT. IN ADDITION, REVLIMID(R) (lenalidomide) MUST ONLY BE DISPENSED TO PATIENTS WHO ARE REGISTERED AND MEET ALL THE CONDITIONS OF THE RevAssist(R) PROGRAM.

2. HEMATOLOGIC TOXICITY (NEUTROPENIA AND THROMBOCYTOPENIA).

THIS DRUG IS ASSOCIATED WITH SIGNIFICANT NEUTROPENIA AND THROMBOCYTOPENIA. EIGHTY PERCENT OF PATIENTS WITH DEL 5q MYELODYSPLASTIC SYNDROMES HAD TO HAVE A DOSE DELAY/REDUCTION DURING THE MAJOR STUDY. THIRTY-FOUR PERCENT OF PATIENTS HAD TO HAVE A SECOND DOSE DELAY/REDUCTION. GRADE 3 OR 4 HEMATOLOGIC TOXICITY WAS SEEN IN 80% OF PATIENTS ENROLLED IN THE STUDY. PATIENTS ON THERAPY FOR DEL 5q MYELODYSPLASTIC SYNDROMES SHOULD HAVE THEIR COMPLETE BLOOD COUNTS MONITORED WEEKLY FOR THE FIRST 8 WEEKS OF THERAPY AND AT LEAST MONTHLY THEREAFTER. PATIENTS MAY REQUIRE DOSE INTERRUPTION AND/OR REDUCTION. PATIENTS MAY REQUIRE USE OF BLOOD PRODUCT SUPPORT AND/OR GROWTH FACTORS. (SEE DOSAGE AND ADMINISTRATION)

3. DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM.

This drug has demonstrated a significantly increased risk of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients with multiple myeloma who were treated with REVLIMID(R) (lenalidomide) combination therapy. Patients and physicians are advised to be observant for the signs and symptoms of thromboembolism. Patients should be instructed to seek medical care if they develop symptoms such as shortness of breath, chest pain, or arm or leg swelling. It is not known whether prophylactic anticoagulation or antiplatelet therapy prescribed in conjunction with REVLIMID(R) (lenalidomide) may lessen the potential for venous thromboembolic events. The decision to take prophylactic measures should be done carefully after an assessment of an individual patient's underlying risk factors.

You can get information abo
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:11/26/2014)...  Cohen, Placitella & Roth, PC is investigating ... Nymox Pharmaceutical Corporation ("Nymox" or "Company") (NASDAQ: ... 31, 2011 through November 2, 2014 ("Class Period").  ... its officers and directors publically disseminated materially false ... and 20(a) of the Securities Exchange Act of ...
(Date:11/26/2014)... -- Over 100 million adults suffer from chronic pain and ... Chronic and acute pain dramatically impacts quality of life. ... the need for non-surgical, interventional solutions and medication management ... October 28th, a new pain management center opened its ... community.  This new facility boasts cutting edge technologies and ...
(Date:11/26/2014)... , Nov. 26, 2014 Zynerba ... the development of innovative transdermal synthetic cannabinoid treatments, today ... Jaffray 26th Annual Healthcare Conference 2014. The conference will ... York Palace in New York . ... present at 4:50 pm on Tuesday, December 2. ...
Breaking Medicine Technology:Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 3New Pain Management Center Opens in Cumberland, Md. 2Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2
... April 22 Genoptix, Inc. (Nasdaq: GXDX ), a specialized ... for the first quarter 2010 after closing of the NASDAQ Global Select Market ... , , ... , Ph.D., and other members of senior management will take place on the ...
... REDWOOD CITY, Calif. , April 22 Codexis, Inc. announced today ... stock, at $13.00 per share. All shares are being sold by ... an additional 900,000 shares at the initial public offering price to cover overallotments, ... the symbol "CDXS." , , , ...
Cached Medicine Technology:Genoptix, Inc. to Announce First Quarter 2010 Financial Results 2Genoptix, Inc. to Announce First Quarter 2010 Financial Results 3Codexis, Inc. Announces Pricing of Initial Public Offering 2
(Date:11/27/2014)... (PRWEB) November 27, 2014 Jeffrey ... years in the Charlotte area providing audits, reviews, ... services to businesses of varying size across numerous ... owners to meet all of their accounting and ... through the QuickBooks ProAdvisor Program. When asking Mr. ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 VogueQueen.com is ... items for ladies across the world. As the premier ... accessories, VogueQueen.com is proud to release a huge selection ... high quality outfits, it is also providing many beautiful ... VogueQueen prom gowns at discounted prices. , “VogueQueen.com ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 Dr. Ronald Receveur, ... has a few oral health tips before patients dig ... offers Louisville and New Albany affordable cosmetic dentistry, ... high in starch and sugar. While the staff wishes everyone ... helpful tips for how patients can enjoy a feast that ...
(Date:11/27/2014)... children to help with chores while they are home from ... boosts self-esteem, and above all, helps parents maintain a somewhat ... how do you encourage your children to want to help? ... Child Development Journal, there is. The study found that adults’ ... to lend a hand. , The study found that ...
(Date:11/27/2014)... Ethane Web Technologies, which is an ... reputation management service. , The company has designed ... world of internet marketing and algorithms of major search ... Web Technologies does not work with the same strategy ... to reach a conclusion what will work for the ...
Breaking Medicine News(10 mins):Health News:Jeffrey Carlini becomes Intuit Proadvisor and receives QuickBooks certification 2Health News:A New Collection of Sexy Prom Dresses Has Been Released by the Reliable Online Supplier VogueQueen.com 2Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 2Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 3Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 4Health News:Ethane Web Technologies Announces Online Reputation Management Service 2
... reports little coronary benefit, regardless of when treatment begins , ... not lower the odds of heart trouble in women who ... of menopause, a new study reports. , In fact, the ... attacks for the first two years of use. , ...
... ... Awards (FOYA) were announced by the program’s sponsors, ISPE, INTERPHEX, and Pharmaceutical Processing ... their operations to yield top quality products. Two of this year’s winning companies ... ...
... ... Green” to the Next Level., , ... Tampa, FL (PRWEB) February 18, 2010 -- Super Green Technologies, ... tankless water heaters on the market today. Super Green Technologies water heaters utilize ...
... Van Andel Research Institute (VARI) researchers have found a ... currently the first line of defense against clear cell renal ... Most patients who show a positive response to sunitinib develop ... Kidney cancer is among the 10 most common cancers ...
... due to complications arising from pregnancy and childbirth. Half of ... the King Juan Carlos University (URJC) in Madrid says these ... but rather from a lack of basic healthcare measures. ... situation and of the inequalities between men and women", Jos ...
... ... Global Business to Business (B2B) Video Network , ... Toronto, Canada (PRWEB) February 18, 2010 -- BCS Global ... telepresence solutions, today announced that it has launched the PSVN (Public Switched Video Network) ...
Cached Medicine News:Health News:Early On, Hormone Therapy May Raise Women's Heart Risks 2Health News:Early On, Hormone Therapy May Raise Women's Heart Risks 3Health News:Awards Strengthen Stonhard's Reputation for High-Performing Floors in the World's Most Prominent Pharmaceutical Facilities 2Health News:First Breakthrough in Water Heating Technology! 2Health News:First Breakthrough in Water Heating Technology! 3Health News:VARI findings may help patients with deadly kidney cancer 2Health News:Most maternal deaths in sub-Saharan Africa could be avoided 2Health News:BCS Global Launches PSVN (Public Switched Video Network), an Initiative to Provide a Framework for Inter-Connecting Business to Business Video Networks 2Health News:BCS Global Launches PSVN (Public Switched Video Network), an Initiative to Provide a Framework for Inter-Connecting Business to Business Video Networks 3Health News:BCS Global Launches PSVN (Public Switched Video Network), an Initiative to Provide a Framework for Inter-Connecting Business to Business Video Networks 4Health News:BCS Global Launches PSVN (Public Switched Video Network), an Initiative to Provide a Framework for Inter-Connecting Business to Business Video Networks 5
... flexible, total solution. , ,Kojair Tech Oy has ... A major part of our production is marketed ... the different areas of clean-air needs are a ... is a comprehensive supplier. We are able to ...
... 95% media meets today's ASHRAE ... contaminant reduction. The unique, patented ... DEFIANT filters creates a media ... respect to initial efficiency, average ...
The Universal Knee Positioner(s)™ reduces surgeon fatigue while assisting in the stabilization of a patient's leg during surgury....
BRAT 2 Autologous Blood Recovery System gives performance, speed, versatility, and quality processing. , ,The BRAT 2 is now available with on-board Vacuum, programmability, plasma sequestration, Data...
Medicine Products: